These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://lilianbieh248406.dsiblogger.com/72067890/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide